X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

GAO again recommends improvements to 340B program

By Nicole Longo  |    July 11, 2018
Over the years, the non-partisan Government Accountability Office (GAO) has reviewed various aspects of the 340B program, finding areas for improvement and providing recommendations. The latest...   Read More

ICYMI - Analysis finds higher outpatient drug spending at 340B hospitals

By Nicole Longo  |    June 18, 2018
Did you know 340B hospitals prescribe more medicines or more expensive medicines? A recent analysis by Milliman, commissioned by PhRMA, found hospitals participating in the 340B drug pricing...   Read More

New 340B analysis: Hospitals raking in billions while uncompensated care drops by billions

By Nicole Longo  |    May 15, 2018
  Read More

Patients pay the price when hospitals mark up cancer medicines

By Joe Vandigo  |    April 5, 2018
Two studies released last month reveal how hospitals across the country mark up the price of medicines and deliver a growing share of provider-administered medicines, resulting in higher costs...   Read More

340B Spotlight: How much money are hospitals pocketing under 340B and what are they doing with those profits?

By Nicole Longo  |    March 28, 2018
The once little-known 340B drug discount program, which was designed to help low-income, uninsured or otherwise vulnerable patients access prescription medicines at safety-net facilities, is now a...   Read More

340B Spotlight: Hospital system adds voice to comments about flawed 340B program

By Nicole Longo  |    February 2, 2018
Each week, more and more groups are calling attention to the 340B program and its myriad problems. Here’s a quick recap of some of the latest voices out there.   Read More

340B Spotlight: New pieces of legislation continue momentum to fix 340B program

By Nicole Longo  |    January 18, 2018
In case you missed it, two new pieces of legislation have been introduced to increase oversight of and fix the 340B program. Before the holidays, Representatives Larry Bucshon and Scott Peters...   Read More

340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform

By Nicole Longo  |    October 20, 2017
Evidence that the 340B program has strayed from its congressionally stated intent – and is now benefiting wealthy hospitals instead of patients – has been piling up, and members of Congress have...   Read More

How much are hospitals marking up the price of medicines? The answer may surprise you.

By Robert Zirkelbach  |    October 17, 2017
Hospitals mark up medicine prices, on average, nearly 500 percent, according to a new analysis from the Moran Company that was commissioned by the Pharmaceutical Research and Manufacturers of...   Read More

340B Spotlight: New analysis finds 340B program growth continues to accelerate despite false claims

By Nicole Longo  |    July 13, 2017
This week, Berkeley Research Group (BRG) released a new whitepaper pushing back on the highly misleading claim that 340B sales are only 2 percent of annual U.S. drug sales. Citing a number of...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."